Shire Continues to Deliver Excellent Growth From Cor...( DUBLIN October 30 /- Shire plc (L...),Health

DUBLIN, October 30 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company, announces results for the three months to September 30, 2009.

    Q3 2009 Financial Highlights

                                                               Q3 2009(1)

    Product sales                                        $603 million    -15%

    Product sales from core products(2)                  $532 million    +20%
    Product sales growth from core products at
    constant exchange rates(2)(3)                                        +23%

    Total revenues                                       $667 million    -14%

    Non GAAP operating income                            $134 million    -52%
    US GAAP operating income                              $92 million    -25%
    Non GAAP diluted earnings per ADS                           $0.49    -58%
    US GAAP diluted earnings per ADS                            $0.33  +$0.52

    (1) Figures compare Q3 2009 results with the same period in 2008.

    (2) Core products represent Shire's products excluding ADDERALL XR.

    (3) Sales growth at constant exchange rates ("CER"), which is a Non GAAP
        measure, is calculated after restating Q3 2009 results using Q3 2008
        average foreign exchange rates.

Angus Russell, Chief Executive Officer, commented:

"Shire continues to deliver excellent growth from its core products, which were up 20% over an exceptionally strong Q3 2008. This performance reflects our transformation in the past few years into a global biopharmaceutical company with a proven differentiated strategy and a balanced portfolio of new products which is protected by strong exclusivity and patent protection.

The growth of our core products and continued pro-active cost management are positioning us well to deliver on our unchanged guidance framework for 2009 and our aspiration of growing sa
'/>"/>